Stemcells (STEM) Misses Q2 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/15/2026

1. NVDA
2. SPY
3. CRWV
4. BAC
5. RKLB
6. BLK
7. NOW
8. CAT
9. RXRX
10. MSFT

Go back to Stemcells (STEM) Misses Q2 EPS by 8c

StemCells, Inc. Reports Second Quarter 2014 Financial Results and Provides Business Update

August 12, 2014 4:02 PM EDT

NEWARK, Calif., Aug. 12, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq: STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

"The highlight for the quarter was the release of the first interim data from our ongoing Phase I/II trial in dry age related macular degeneration (AMD)," said Martin McGlynn, president and CEO of StemCells, Inc. "We reported positive clinical findings, including a 70% reduction in... More